AxoGen, Inc. (0HKD.L)
| Previous close | 6.80 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 424 |
| Market cap | 2.456M |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.77 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.AxoGen, Inc. (NASDAQ:AXGN) is largely controlled by institutional shareholders who own 58% of the company
Key Insights Institutions' substantial holdings in AxoGen implies that they have significant influence over the...
GlobeNewswireAxogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
ALACHUA, Fla. and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™. “We are excited to expand our offering in nerve protection with the introduction of this resorbable barrier to support the critical phases of healing for nerve injuries,” said Karen Zaderej, chairman, CEO,
- GlobeNewswire
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call
